Navigation Links
AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
Date:3/20/2008

Physicians Indicate that Most Promising Emerging Therapies Will Not Match the Current Gold-Standard Avastin/Taxol/Paraplatin Regimen's Efficacy,

According to a New Report from Decision Resources

WALTHAM, Mass., March 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the emerging drug Zactima from AstraZeneca will earn 4.7 percent patient share in the treatment of non-small-cell lung cancer (NSCLC) by 2016. Surveyed oncologists indicate that they would prescribe Zactima to 30 percent of their patients with advanced non-small-cell lung cancer. Also, 38 percent of the physicians surveyed indicate they will use Zactima as an adjunct to current therapy rather than as a replacement. Zactima is forecasted to launch in 2008 in the United States and Europe and in 2010 in Japan.

According to the new report entitled Non-Small-Cell Lung Cancer (Advanced): Current Gold-Standard Therapy Continues to Be Most Efficacious; physicians indicate that the most promising emerging therapies for the treatment of non-small-cell lung cancer will not match the current gold- standard regimen comprising Roche/Genentech/Chugai's Avastin, Bristol-Myers Squibb's Taxol, and Bristol-Myers Squibb's Paraplatin.

"Although some therapies in development for advanced NSCLC hold promise, most have efficacy, safety and tolerability, and/or delivery features that merit inferior scores compared with the Avastin/Taxol/Paraplatin regimen," said Andrew Merron, Ph.D., analyst at Decision Resources. "A therapy's effect on overall survival is the attribute that most influences prescribing decisions in advanced non-small-cell lung cancer. Data and the opinions of interviewed thought leaders indicate that Avastin/Taxol/Paraplatin has advantages over the sales-leading combination of Sanofi-Aventis's Taxotere and Bristol-Myers Squibb's Platinol-AQ on overall survival."

About the Report

Non-Small-Cell Lung Cancer (Advanced): Current Gold-Standard Therapy Continues to Be Most Efficacious is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price- per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
2. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
3. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
4. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
5. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
6. LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems
7. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
8. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
9. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
10. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
11. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... NextSteps 2017, ... North America this May on the following dates: , ?    London, UK ... Chairman of the Learning and Performance Institute will be the opening keynote ...
(Date:4/25/2017)... ... ... As part of the Stago EdVantage Virtual University Virtual Event, ... order to illuminate this clinical problem for people unfamiliar with the topic. , DIC ... high degree of morbidity and mortality. DIC is a confusing disorder from both diagnostic ...
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced T·rej·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
(Date:4/25/2017)... ... 2017 , ... Leaders of Quorum Review IRB and Kinetiq ... at this week’s Association of Clinical Research Professionals (ACRP) 2017 Meeting & Expo ... , "We are excited to present subject matter expertise on topics that impact the ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):